A3P Biomedical AB is a Swedish company with a global mission – to radically improve precision in prostate cancer diagnostics and treatment.

The company’s leading product is Stockholm3, a clinically and commercially validated blood test for early detection of aggressive prostate cancer. The test has been developed by researchers at Karolinska Institutet.

The company has a wholly owned subsidiary laboratory for analyzing Stockholm3. The laboratory works in accordance with the Patient Safety Act 2010: 659 and is registered as a care provider with the Swedish Health and Care Inspectorate (IVO).

A3P Biomedical also has a wholly owned subsidiary that provides algorithm-based test results in a cloud-based system for handling clinical data in accordance with GDPR. The company is ISO 13485 certified and the software complies with IEC 62304 standard for medical technology software.

Information about the board and management.